Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions
Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions
复制标题
DOI：
10.3346/jkms.2005.20.5.770
复制
发表时间：
2005-10-01
影响因子：
4.5
通讯作者：
Myong, NH
中科院分区：
文献类型：
--
作者：
Myong, NH
细胞表面Fas表达缺失是细胞凋亡抵抗的主要途径，被认为是肿瘤发生、发展的重要机制。为探讨Fas和FasL在非小细胞肺癌(NSCLC)发生发展中的作用，探讨Fas和FasL在110例非小细胞肺癌(NSCLC)中的表达及其与P53、bcl2过表达的关系。组织芯片免疫组织化学分析显示，很大比例(60%)的NSCLC患者存在膜性Fas表达缺失。Fas阴性患者的生存率明显低于Fas阳性患者。Fas受体表达缺失多见于晚期和高结节状态。与正常肺组织相比，大多数非小细胞肺癌组织中FasL蛋白表达增加(%)。P53和bcl2的过度表达与Fas的表达无关。结论：Fas膜表达降低作为抗细胞凋亡的一种机制被认为在肺癌的发生中起重要作用，可能预示着不良的生存和不良的预后。FasL的高表达被认为是NSCLC免疫逃逸的基础。这种罕见的bcl2过表达表明，这种抗凋亡蛋白不太可能在NSCLC的凋亡抵抗中发挥作用。
Lack of surface Fas expression is a main route for apoptotic resistance which is considered an important mechanism of tumorigenesis and tumor progression. Fas and FasL expressions in 110 non-small cell lung carcinomas (NSCLCs) were investigated to evaluate their roles in pulmonary carcinogenesis and to examine the clink copathologic significance of Fas expression with its relationship with p53 and bcl-2 overexpressions. Immunohistochemical analysis using tissue microarray demonstrated that a large proportion of NSCLC patients (60%) showed lack of membranous Fas expression. The Fas-negative cases revealed the significantly lower survival rate than Fas-positive ones. Also, the loss of Fas receptor expression was found more frequently in advanced stage and higher nodal status. FasL protein was increased in most NSCLCs (89%) compared to normal lungs. p53 and bcl-2 overexpressions showed no association with Fas expression. Conclusively, reduced membranous Fas expression as a mechanism of apoptotic resistance is considered to play an important part of the pulmonary carcinogenesis, which may predict poor survival and have a bad prognostic influence. Increased FasL expression is thought to be a basis for the immune evasion in NSCLCs. The rare bcl-2 overexpression suggests that this anti-apoptotic protein is unlikely to play a role in the apoptotic resistance of NSCLCs.